Enzo Biochem Inc. (NYSE: ENZ) today reported that scientists from its Enzo Therapeutics group presented a podium session entitled “ The Presence of Sulfated Tyrosine In Scelerostin and Dkk1 Ligands and its Effect on Wnt Signaling ” at the WNT 2011 conference in Los Angeles Thursday, June 30, 2011.
“Our scientific team has identified a new target on a key modulator of the Wnt system that not only allows for development of novel antibodies for the modulation of this important pathway, but it has also identified a small peptide that can accomplish the same modulation without the need for antibodies,” said Dr. Elazar Rabbani, CEO of Enzo Biochem.
“We believe that this exciting discovery opens up the possibility for the development of a new class of therapeutic products for the treatment of numerous important diseases, including cancer and metabolic disorders,” added Dr. Rabbani. “Moreover, Enzo’s discovery could be important in the development of companion diagnostics and prognostics that could be invaluable in the effective management of patients afflicted with these conditions.”
The work performed by Enzo’s scientific team showed the existence of an entirely new class of modification of scelerostin and Dkk proteins which exhibit significant biological function. These proteins have been shown to inhibit the Wnt signaling pathway, and therefore mediate the development of numerous diseases. As an example, fluctuation in the level of these proteins has been shown to affect such serious conditions as osteoporosis. It has been reported that anti-scelerostin anabolics are among the most exciting development in the treatment of bone disorders.Osteoporosis is a major women’s health issue, affecting 30% of post-menopausal women. For the 40 million persons in the US who have or are at risk for developing osteoporosis—10 million of whom are currently in treatment for osteoporosis—and their physicians, the availability of an oral peptide would be a novel and appealing option as compared to current injectable treatment options.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV